Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Schweizerische Medizinische Wochenschrift|March 30, 1991
[Myocardial infarction in pregnancy]U N Dürst, M K Hohl, F Kocher, et al.
Der Urologe. Ausg. A|March 1, 1995
[Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results]R Bachor, F Kocher, F Gropengiesser, et al.
Intensive Care Medicine|January 1, 1991
The consequences of continuous haemofiltration on lung mechanics and extravascular lung water in a porcine endotoxic shock modelB Stein, E Pfenninger, A Grünert, et al.
Virology|December 27, 2017
Adaptive evolution influences the infectious dose of MERS-CoV necessary to achieve severe respiratory diseaseMadeline G Douglas, Jacob F Kocher, Trevor Scobey, et al.
Radiology|May 1, 1995
2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretationJ C Stollfuss, G Glatting, H Friess, et al.
Journal of Mass Spectrometry : JMS|July 1, 1996
Kinetic analysis of the reaction between d(TTGGCCAA) and [Pt(NH3)3(H2O)]2+ by enzymatic degradation of the products and ESI and MALDI mass spectrometriesF Gonnet, F Kocher, J C Blais, et al.
Journal of Dentistry|June 20, 2022
Efficacy and hazards of 425 nm oral cavity light dosing to inactivate SARS-CoV-2Max A Stockslager, Jacob F Kocher, Leslee Arwood, et al.
Lung Cancer (Amsterdam, Netherlands)|July 22, 2014
Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial)F Kocher, A Pircher, A Mohn-Staudner, et al.
The Journal of Infectious Diseases|October 4, 2017
Emergence of Novel Human Norovirus GII.17 Strains Correlates With Changes in Blockade Antibody EpitopesLisa C Lindesmith, Jacob F Kocher, Eric F Donaldson, et al.
ESMO Open|February 6, 2026
Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trialT Fuereder, K Klinghammer, D Hahn, et al.
Pageof 4